Characterisation of mesenchymal stromal cells in clinical trial reports: analysis of published descriptors.
Cell therapy
Characterisation
Clinical trial
Mesenchymal stem cells
Mesenchymal stromal cells
Regenerative medicine
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
22 06 2021
22 06 2021
Historique:
received:
29
01
2021
accepted:
06
06
2021
entrez:
23
6
2021
pubmed:
24
6
2021
medline:
13
7
2021
Statut:
epublish
Résumé
Mesenchymal stem or stromal cells are the most widely used cell therapy to date. They are heterogeneous, with variations in growth potential, differentiation capacity and protein expression profile depending on tissue source and production process. Nomenclature and defining characteristics have been debated for almost 20 years, yet the generic term 'MSC' is used to cover a wide range of cellular phenotypes. Against a documented lack of definition of cellular populations used in clinical trials, our study evaluated the extent of characterisation of the cellular population or study drug. A literature search of clinical trials involving mesenchymal stem/stromal cells was refined to 84 papers upon application of pre-defined inclusion/exclusion criteria. Data were extracted covering background trial information including location, phase, indication, tissue source and details of clinical cell population characterisation (expression of surface markers, viability, differentiation assays and potency/functionality assays). Descriptive statistics were applied, and tests of association between groups were explored using Fisher's exact test for count data with simulated p value. Twenty-eight studies (33.3%) include no characterisation data. Forty-five (53.6%) reported average values per marker for all cell lots used in the trial, and 11 (13.1%) studies included individual values per cell lot. Viability was reported in 57% of studies. Differentiation was discussed: osteogenesis (29% of papers), adipogenesis (27%), and chondrogenesis (20%) and other functional assays arose in 7 papers (8%). The extent of characterisation was not related to the clinical phase of development. Assessment of functionality was very limited and did not always relate to the likely mechanism of action. The extent of characterisation was poor and variable. Our findings concur with those in other fields including bone marrow aspirate and platelet-rich plasma therapy. We discuss the potential implications of these findings for the use of mesenchymal stem or stromal cells in regenerative medicine, and the importance of characterisation for transparency and comparability of literature.
Sections du résumé
BACKGROUND
Mesenchymal stem or stromal cells are the most widely used cell therapy to date. They are heterogeneous, with variations in growth potential, differentiation capacity and protein expression profile depending on tissue source and production process. Nomenclature and defining characteristics have been debated for almost 20 years, yet the generic term 'MSC' is used to cover a wide range of cellular phenotypes. Against a documented lack of definition of cellular populations used in clinical trials, our study evaluated the extent of characterisation of the cellular population or study drug.
METHODS
A literature search of clinical trials involving mesenchymal stem/stromal cells was refined to 84 papers upon application of pre-defined inclusion/exclusion criteria. Data were extracted covering background trial information including location, phase, indication, tissue source and details of clinical cell population characterisation (expression of surface markers, viability, differentiation assays and potency/functionality assays). Descriptive statistics were applied, and tests of association between groups were explored using Fisher's exact test for count data with simulated p value.
RESULTS
Twenty-eight studies (33.3%) include no characterisation data. Forty-five (53.6%) reported average values per marker for all cell lots used in the trial, and 11 (13.1%) studies included individual values per cell lot. Viability was reported in 57% of studies. Differentiation was discussed: osteogenesis (29% of papers), adipogenesis (27%), and chondrogenesis (20%) and other functional assays arose in 7 papers (8%). The extent of characterisation was not related to the clinical phase of development. Assessment of functionality was very limited and did not always relate to the likely mechanism of action.
CONCLUSIONS
The extent of characterisation was poor and variable. Our findings concur with those in other fields including bone marrow aspirate and platelet-rich plasma therapy. We discuss the potential implications of these findings for the use of mesenchymal stem or stromal cells in regenerative medicine, and the importance of characterisation for transparency and comparability of literature.
Identifiants
pubmed: 34158116
doi: 10.1186/s13287-021-02435-1
pii: 10.1186/s13287-021-02435-1
pmc: PMC8220718
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
360Subventions
Organisme : Versus Arthritis
ID : 21156
Pays : United Kingdom
Références
Front Med (Lausanne). 2018 May 28;5:158
pubmed: 29911104
Cell Commun Signal. 2011 May 14;9:12
pubmed: 21569606
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
J Am Acad Orthop Surg. 2019 Jan 15;27(2):e50-e63
pubmed: 30300216
Cell. 2007 Oct 19;131(2):324-36
pubmed: 17956733
JAMA. 2015 Feb 17;313(7):663-4
pubmed: 25688775
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141887
Stem Cells. 2006 May;24(5):1294-301
pubmed: 16410387
Cochrane Database Syst Rev. 2019 Jan 30;1:CD009768
pubmed: 30697701
Stem Cell Reports. 2016 Jun 14;6(6):787-797
pubmed: 27185282
Syst Rev. 2012 Nov 29;1:60
pubmed: 23194585
J Clin Epidemiol. 2006 Nov;59(11):1134-49
pubmed: 17027423
Cell Stem Cell. 2014 Feb 6;14(2):141-5
pubmed: 24506881
Annu Rev Cell Dev Biol. 2014;30:677-704
pubmed: 25150008
Stem Cells Int. 2019 Apr 9;2019:9628536
pubmed: 31093291
Nat Med. 2013 Jan;19(1):35-42
pubmed: 23296015
Clin Pharmacol Ther. 2007 Sep;82(3):241-3
pubmed: 17700588
Stem Cell Rev Rep. 2012 Jun;8(2):375-92
pubmed: 21892603
Stem Cells Dev. 2013 Oct 1;22(19):2606-18
pubmed: 23676112
Cell Stem Cell. 2014 Aug 7;15(2):154-68
pubmed: 24953181
Stem Cell Reports. 2017 May 9;8(5):1190-1201
pubmed: 28416287
J Med Ethics. 2017 Nov;43(11):744-746
pubmed: 28356490
Blood. 2007 Feb 15;109(4):1743-51
pubmed: 17062733
Circ Res. 2015 Aug 28;117(6):576-84
pubmed: 26148930
Front Immunol. 2019 May 16;10:1112
pubmed: 31164890
Stem Cells Transl Med. 2017 Jun;6(6):1445-1451
pubmed: 28452204
Cell Transplant. 2013;22(2):279-85
pubmed: 23006344
Haematologica. 2009 Feb;94(2):173-84
pubmed: 19066333
J Bone Joint Surg Am. 2016 Sep 21;98(18):1511-21
pubmed: 27655978
Open Orthop J. 2011;5(Suppl 2):253-60
pubmed: 21966340
Nature. 2010 Aug 12;466(7308):829-34
pubmed: 20703299
N Engl J Med. 2018 Mar 8;378(10):954-959
pubmed: 29514023
J Bone Joint Surg Am. 2017 Oct 18;99(20):1769-1779
pubmed: 29040132
Sci Transl Med. 2019 Feb 20;11(480):
pubmed: 30787168
Cytokine Growth Factor Rev. 2009 Oct-Dec;20(5-6):419-27
pubmed: 19926330
Lancet. 2010 Aug 14;376(9740):514
pubmed: 20709228
Stem Cell Res Ther. 2016 Jan 11;7:4
pubmed: 26753846
Tissue Eng Part A. 2010 Aug;16(8):2415-7
pubmed: 20412005
Front Immunol. 2019 Jun 04;10:1228
pubmed: 31214185
Cytotherapy. 2013 Jun;15(6):641-8
pubmed: 23570660
Stem Cells Int. 2018 Aug 19;2018:8031718
pubmed: 30210552
Stem Cells. 2018 Apr;36(4):602-615
pubmed: 29341339
J Bone Joint Surg Am. 2017 May 17;99(10):809-819
pubmed: 28509821
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
J Immunol Res. 2018 Sep 9;2018:7232717
pubmed: 30271793
Stem Cells. 2010 Apr;28(4):788-98
pubmed: 20127798
J Bone Joint Surg Am. 2018 Mar 21;100(6):517-525
pubmed: 29557869
Eur J Clin Invest. 2019 Apr;49(4):e13072
pubmed: 30690709
JAMA. 2001 Apr 18;285(15):1992-5
pubmed: 11308436
Regen Med. 2018 Jan;13(1):19-27
pubmed: 29327974
EMBO J. 2013 May 29;32(11):1489-95
pubmed: 23644381
NPJ Regen Med. 2019 Dec 2;4:22
pubmed: 31815001
Cell Transplant. 2013;22(7):1201-11
pubmed: 23044363
Stem Cell Reports. 2015 Jun 9;4(6):1004-15
pubmed: 26070611
J Bone Joint Surg Am. 2019 May 15;101(10):904-911
pubmed: 31094982
Regen Med. 2019 Jun;14(6):595-611
pubmed: 31115266
Stem Cells Transl Med. 2017 Dec;6(12):2173-2185
pubmed: 29076267
Cell Stem Cell. 2018 Jun 01;22(6):824-833
pubmed: 29859173
Neural Regen Res. 2020 Jan;15(1):75-77
pubmed: 31535654
Nature. 2012 Jan 25;481(7382):457-62
pubmed: 22281595
Front Immunol. 2019 Jul 31;10:1645
pubmed: 31417542
Stem Cells. 2016 May;34(5):1135-41
pubmed: 26840390
Int Sch Res Notices. 2016 Mar 22;2016:1346026
pubmed: 27382637
Nature. 2018 Sep;561(7724):455-457
pubmed: 30258150
Stem Cells Transl Med. 2019 Nov;8(11):1135-1148
pubmed: 31313507